skip to main content

Lowenstein Sandler LLP | The contents of this website contain attorney advertising. | Results may vary depending on your particular facts and legal circumstances.

Search
Smart Search Icon
Header Search

Recent Searches

Clear all Searches

Relevant Insights

Featured Content

view all search results
Search Close
Hamburger
profile Icon for Mobile

Kate Basmagian

Partner
Chair, ESG Practice

New York
T: +1 646.414.6941 F: +1 973.535.3341 kbasmagian@lowenstein.com
  • BIO
  • EXPERIENCE
  • NEWS & INSIGHTS

See more section

Kate Basmagian is a partner in the Capital Markets & Securities Group and Chair of the firm’s ESG practice. She has extensive experience advising public companies and their Boards of Directors on securities regulation and compliance, capital raising transactions and corporate governance and ESG matters. She has represented both issuers and underwriters in public offerings spanning multiple industries. Kate leverages the experience she gained at The Estée Lauder Companies Inc. and PepsiCo, Inc. to help offer practical, business-oriented solutions to her clients.

  • Advising Altair (NASDAQ: ALTR), a global leader in computational intelligence, in connection with its $10.6 billion definitive agreement to be acquired by Siemens, a leading technology company focused on industry, infrastructure, mobility, and healthcare.
  • Represented The Estée Lauder Companies Inc. (“ELC”) in a transaction to complete its acquisition of DECIEM Beauty Group Inc. (“DECIEM”), a Canadian-based, vertically integrated, multi-brand company for approximately $860 million. Lowenstein Sandler had previously represented ELC in its initial investment in DECIEM in 2017 and again when ELC increased its stake in DECIEM to become a majority owner of the company in 2021. Net of cash, ELC’s total investment in DECIEM was approximately $1.7 billion.
  • Represented Celldex Therapeutics, Inc. (NASDAQ: CLDX) in its $460.5 million public offering of common stock.
  • Represented Celldex Therapeutics, Inc. (NASDAQ: CLDX) in its at the market offering of up to $300.0 million of common stock.

  • Represented Phreesia, Inc. (NYSE: PHR), a leader in patient intake, outreach and activation, in its acquisition of Access eForms, LLC, a provider of integrated paperless forms and workflows for healthcare facilities.

  • Represented Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, in a $4 million registered direct offering of commons stock and warrants.
  • Represented ZyVersa Therapeutics, Inc., a clinical-stage specialty biopharmaceutical company, in its agreement with blank-check SPAC Larkspur Health Acquisition Corp. (NASDAQ: LSPR) to enter into a definitive business combination agreement, resulting in an estimated pro forma company valuation of approximately $108.92 million.
  • Represented Fir Tree Capital Management as the selling stockholder in the public offering of 8.5 million shares of common stock in Amplify Energy Corp (NYSE: AMPY), an upstream company focused on the acquisition, production, and development of oil and gas properties in the U.S.
SEE MORE

Education

  • New York University School of Law (J.D. 2010)

    University of California, Los Angeles (B.A. 2006), English

Admissions

  • New York

Related Areas

Subscribe